Rheumatoid arthritis is a progressive disease of the joint structure that may be localized or systemic. It varies significantly in severity, producing symptoms that range from minor aches to severe disability and joint deformity. While rheumatoid arthritis can be diagnosed at any age, for childhood to the later years, it most commonly presents with significant symptoms at about middle age. From that point, the disease can progress quickly, slowly or virtually not at all. With an aging population, the unmet need for therapeutics in this area is expected to increase simultaneously.
This report discusses the world market for rheumatoid arthritis therapeutics in terms of its potential in the growing older (aged 45-plus years) population in the United States as opposed to a rehash of experienced and projected revenues. There are several reason for this:
-
A large number of therapeutic applications for rheumatoid arthritis are currently in development and are based on advanced technology in drug design and development.
- Because much of the potential use of new therapeutics is not associated with commonly available databases, it is often impossible to determine their level and type (monotherapy or part of polytherapy) of their application in the growing market environments.
- The status of the current market in terms of revenues is misleading of the potential market as a whole. It does not allow for the understanding of the potential of unmet need, which will be discussed in the various sections of this report, and is in no way reflected by the current revenue picture for rheumatoid arthritis. The difference can be as stark as the difference between the surface of the sun and the dark side of the moon.
The current United States total available market (TAM) potential for rheumatoid arthritis therapeutics is approximately $48.5 billion. However, only some $16.6 billion (34.2% of the TAM) is considered to be the serviceable available market (SAM).
Modern medical science is moving rapidly to determine the pathological mechanisms involved in the development and progression of rheumatoid arthritis. Principally these center on the action of the immune system. As our understanding of these mechanisms increase, so does our ability to design newer and more effective therapies.
This volume of the Markets in Geriatric Medicine Series looks at the new evidence concerning the mechanisms involved in the pathology and the specific molecules that the body uses to regulate the process. It also explores current treatment modalities for rheumatoid arthritis, including non-steroidal anti-inflammatory drugs (NSAIDs), disease modifying anti-rheumatic drugs (DMARDs) and corticosteroids. It also looks at the new and emerging research and development efforts into the discovery of advanced therapeutic products that focus on immune system targets such as tumor necrosis factor-á (TNF-á), interleukins-1 (IL-1), interleukins-6 (IL-6), interleukin-15 (IL-15) and p38-MAP-kinase. The report discusses the latest in progress towards clinical development of immunoregulatory molecules that may be introduced over the next decade for the treatment of rheumatoid arthritis at its most basic levels.
Chapter One: Executive Summary
- Background
- Scope and Methodology
- Size and Growth of Market
- Market Trends and Factors
Chapter Two: Introduction
- Background
- Population Demographics
- Epidemiology and Pathology of Rheumatoid Arthritis
Chapter Three: Rheumatoid Arthritis Therapeutics
- Current Approaches
- Approaches to Rheumatoid Arthritis Therapy
- Patient Education
- Rest and Exercise
- Diet
- Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
- Disease-Modifying Anti-Rheumatic Drugs (DMARDs)
- Steroids (Corticosteroids, Glucocorticoids)
- Cytokine Targeted Therapy
- Other Approaches
- Emerging Therapeutic Approaches
- Tumor Necrosis Factor-a (TNF-a) Inhibitors
- Interleukin-1 (IL-1)Inhibitors
- p38 MAP Kinase Inhibitors
- Interleukin-6 (IL-6) Inhibitors
- Interleukin-15 (IL-15) Inhibitors
- HC-gp-39 (Human Cartilage-glycoprotein-39) Desensitizers
- C5 (Complement) Inhibitors
- Vaccines
- Other Approaches
Chapter Four: Market Analysis
- Market Size and Growth
- Competitive Outlook
- Market Trends
Chapter Five: Company Profiles
- Overview
- Abbott Laboratories
- AstraZeneca
- Biogen, Inc.
- Chugai Pharmaceuticals USA, LLC
- Corixa Corporation
- Fujisawa Pharmaceutical Co., Ltd.
- Lifestyle Therapeutics - Camrose, Inc.
- Medarex, Inc.
- Pfizer
- Schering-Plough
- Vertex Pharmaceuticals, Inc.
- Viron Therapeutics, Inc.
- Wyeth
Chapter Six: Conclusions and Strategic Implications
- First Conclusion
- Second Conclusion
- Third Conclusion
- Fourth Conclusion
- Fifth Conclusion
- Sixth Conclusion
- Seventh Conclusion
- Eighth Conclusion
- Ninth Conclusion
- Tenth Conclusion
APPENDIX A: Company Directory
List of Exhibits
Chapter One: Executive Summary
- Table 1-1: Estimated TAM Potential for the Age-Related Segments for Rheumatoid Arthritis Therapeutics in the United States Markets, 2003-2013
- Table 1-2: Estimated SAM Potential for the Age-Related Segments for Rheumatoid Arthritis Therapeutics in the United States Markets 2003-2013
- Figure 1-1: Trending in the TAM and SAM Potential for Rheumatoid Arthritis Therapeutics in the United States in the Middle-Aged and Elderly Market Segments 2003-2013
- Figure 1-2: Trending in the TAM and SAM Potential for Rheumatoid Arthritis Therapeutics in the United States in the 45- to 54-Year-Old Market Segment 2003-2013
- Figure 1-3: Trending in the TAM and SAM Potential for Rheumatoid Arthritis Therapeutics in the United States in the 55- to 64-Year-Old Market Segment 2003-2013
- Figure 1-4: Trending in the TAM and SAM Potential for Rheumatoid Arthritis Therapeutics in the United States in the 65- to 74-Year-Old Market Segment 2003-2013
- Figure 1-5: Trending in the TAM and SAM Potential for Rheumatoid Arthritis Therapeutics in the United States in the 75+ Year-Old Market Segment 2003-2013
Chapter Two: Introduction
- Figure 2-1: Growth of the World’s Elderly (60+ Years) Population 2001-2025
- Figure 2-2: Population Distribution of the United States by Age and Sex 1999 and 2025
- Figure 2-3: The Growing United States Population 2003-2013
- Figure 2-4: Increasing Median Age of the United States Population
- Figure 2-5: Increasing Mean Age of the United States Population
- Table 2-1: Aging of the United States Population in the Age Groups 45 Years and Older 2003-2013
- Figure 2-6: Aging Trends in the United States Population for the Age
- Groups 45 Years and Older 2003-2013
- Figure 2-7: Changes in the Composition of the 45+Year-Old and Older Age Segment in the United States 2003 and 2013
- Table 2-2: Older Population Groups as Percentages of the Total United States Population by Age Group 2003-2013
- Figure 2-8: Aging Trends by Percentage of the United States Population for the Age Groups 45 Years and Older 2003-2013
- Table 2-3: Prevalence of Rheumatoid Arthritis Cases in the United States
- for the Total Population and Those 45 Years of Age and Older 2003-2013 Figure 2-9: Trending in United States Rheumatoid Arthritis Cases in the 45+ Year Old Age Group 2003-2013
Chapter Three: Rheumatoid Arthritis Therapeutics
- Table 3-1: Currently Marketed Products for the Treatment of Rheumatoid Arthritis
- Table 3-2: Recommended Patient Monitoring for the Administration of DMARDS in the Treatment of Rheumatoid Arthritis Table 3-3: Rheumatoid Arthritis Therapeutics in Development
Chapter Four: Market Analysis
- Table 4-1: United States Total and Serviceable Available Market Potential for Rheumatoid Arthritis Therapeutics 2003-2013
- Figure 4-1: Trending in the United States Total and Serviceable
- Available Market Potential for Rheumatoid Arthritis Therapeutics 2003-2013
- Table 4-2: United States Total and Serviceable Available Market Potential for Rheumatoid Arthritis Therapeutics in the 45+ Age Population 2003-2013
- Figure 4-2: Trending in the United States Total and Serviceable Available Market Potential for Rheumatoid Arthritis Therapeutics for the 45- to 54-Year-Old Age Group 2003-2013
- Figure 4-3: Trending in the United States Total and Serviceable Available Market Potential for Rheumatoid Arthritis Therapeutics for the 55- to 64-Year-Old Age Group 2003-2013
- Figure 4-4: Trending in the United States Total and Serviceable Available Market Potential for Rheumatoid Arthritis Therapeutics for the 65- to 74-Year-Old Age Group 2003-2013
- Figure 4-5: Trending in the United States Total and Serviceable Available Market Potential for Rheumatoid Arthritis Therapeutics for the 65- to 74-Year-Old Age Group 2003-2013
- Table 4-6: Currently Marketed and Potential Competitive Products for the Treatment of Rheumatoid Arthritis
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook